Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06637072 · ClinicalTrials.gov registry record · Phase 4
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
A Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by argenx.
- Active
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
- 13
- Study locations
NCT06637072: Active Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by argenx.
NCT06637072 is a Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy that is active but no longer recruiting, run by argenx. The registered enrollment target is 23 participants, below the 158-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06637072, a Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy, is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod PH20 SC
Study Locations (13)
Texas
- National Neuromuscular Research Institute - Austin
- Horizon Clinical Research: Gill Neuroscience - Cypress
- Northwest Houston Neurology - Cypress - Cypress
- Cedar Health Research - Dallas - Dallas
Florida
- Neurology Associates PA - Maitland
- Visionary Investigators Network - Miami
Tennessee
- Erlanger Neuroscience Institute - Chattanooga
- Vanderbilt University Medical Center - Nashville
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Illinois
- Northwestern Memorial Hospital - Chicago
Louisiana
- Velocity Clinical Research - Lafayette
Michigan
- SRI International - ClinEdge - Plymouth
North Carolina
- Velocity Clinical Research - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-12-10 |
| Est. Completion | 2026-02-23 |
| Phase | Phase 4 |
What the registry record for NCT06637072 still lists
NCT06637072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 158-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod PH20 SC is the first listed.
NCT06637072 lists 13 locations in 8 states (Texas, Florida, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06637072 about?
NCT06637072 is a clinical study titled "A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC". This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
What is the current status of trial NCT06637072?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2024-12-10. Estimated completion is 2026-02-23.
What conditions does trial NCT06637072 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT06637072?
The interventions under investigation include: Efgartigimod PH20 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT06637072?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06637072 being conducted?
This trial has 13 study locations across District of Columbia, Florida, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06637072's enrollment target sits among peer trials
23 10th of 11 higher than 2 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI